AbbVie Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a stark contrast between operational success and financial instability. While the commercial transition to Skyrizi and Rinvoq is clearly working, the company's balance sheet is under significant pressure. The massive swing in net income, driven by contingent consideration adjustments, underscores the volatility associated with AbbVie's aggressive acquisition strategy to offset the Humira patent cliff. Investors are now faced with a trade-off between a high-growth, diversifying product pipeline and a deteriorating capital structure. The company's ability to maintain its dividend and buyback programs while servicing $8 billion in new debt will depend on the successful launch of new indications and the resolution of ongoing tax and product liability litigations.